Daniel Kenny, chief executive officer, commented:
"After a lengthy and complex review it is clear that the company is now well on its way to obtaining the CE Mark this year.
"I am pleased with the progress that the OncoSil team has made over the past 12 months in securing the IDE from the FDA, and the on-boarding of top tier recruitment sites in Australia, UK and the US.
"OncoSil is well positioned to collect the supplemental data quickly and to finalise our post marketing follow up program to secure the CE Mark in 2017."
The CE Mark review for the Primary Liver indication (HCC) is ongoing.
Daniel Kenny, chief executive officer, commented:"After a...
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $49.19M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.7¢ | $69.42K | 8.685M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 67 | 28673846 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 7597003 | 11 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| OSL (ASX) Chart |
